Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer

Published:2018-06-12 Issue:45 Volume:9 Page:27789-27796
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hata Akito¹,Harada Daijiro²,Okuda Chiyuki¹,Kaji Reiko¹,Masuda Yoshio³,Takechi Yoshika⁴,Kozuki Toshiyuki²,Nogami Naoyuki²,Katakami Nobuyuki¹

Affiliation:

1. Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan

2. Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

3. Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan

4. Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051;Scientific Reports;2024-02-15

2. Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment;Thoracic Cancer;2023-11-14

3. Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment;Scientific Reports;2023-11-09

4. Influence of using history of immune checkpoint inhibitor therapy for neutropenia caused by combination therapy of ramucirumab and docetaxel;PHARMAZIE;2022

5. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study;Journal of Geriatric Oncology;2021-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3